Stock Scorecard



Stock Summary for AnaptysBio Inc (ANAB) - $22.52 as of 3/28/2024 8:58:16 PM EST

Total Score

8 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ANAB

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ANAB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ANAB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for ANAB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for ANAB

Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients 3/16/2024 3:22:00 PM
What Makes AnaptysBio, Inc. ( ANAB ) a New Buy Stock 3/14/2024 4:00:00 PM
Wall Street Analysts Believe AnaptysBio, Inc. ( ANAB ) Could Rally 69.62%: Here's is How to Trade 3/14/2024 1:55:00 PM
Is ANI Pharmaceuticals ( ANIP ) Stock Outpacing Its Medical Peers This Year? 3/14/2024 1:40:00 PM
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers - AnaptysBio ( NASDAQ:ANAB ) 3/12/2024 6:48:00 PM
AnaptysBio, Inc. ( ANAB ) Reports Q4 Loss, Tops Revenue Estimates 3/11/2024 9:30:00 PM
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update 3/11/2024 8:15:00 PM
Analysts Estimate Lexicon Pharmaceuticals ( LXRX ) to Report a Decline in Earnings: What to Look Out for 2/29/2024 3:00:00 PM
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting 2/29/2024 2:15:00 PM
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting - AnaptysBio ( NASDAQ:ANAB ) 2/29/2024 2:15:00 PM

Financial Details for ANAB

Company Overview

Ticker ANAB
Company Name AnaptysBio Inc
Country USA
Description AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/9/2024

Stock Price History

Last Day Price 22.52
Last Day Price Updated 3/28/2024 8:58:16 PM EST
Last Day Volume 470,804
Average Daily Volume 347,813
52-Week High 27.50
52-Week Low 13.36
Last Price to 52 Week Low 68.56%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -12.01
Free Cash Flow Ratio 1.54
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 10.87
Total Cash Per Share 14.61
Book Value Per Share Most Recent Quarter 3.31
Price to Book Ratio 6.57
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 33.35
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 26,763,100
Market Capitalization 602,705,012
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -27.11%
Reported EPS 12 Trailing Months -6.08
Reported EPS Past Year -6.08
Reported EPS Prior Year -4.57
Net Income Twelve Trailing Months -163,619,000
Net Income Past Year -163,619,000
Net Income Prior Year -128,724,000
Quarterly Revenue Growth YOY 32.30%
5-Year Revenue Growth 38.65%

Balance Sheet

Total Cash Most Recent Quarter 390,904,000
Total Cash Past Year 390,904,000
Total Cash Prior Year 441,241,000
Net Cash Position Most Recent Quarter 390,904,000
Net Cash Position Past Year 390,904,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 1,375,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 88,103,000
Total Stockholder Equity Prior Year 262,103,000
Total Stockholder Equity Most Recent Quarter 88,103,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.71
MACD Signal -0.28
20-Day Bollinger Lower Band 14.40
20-Day Bollinger Middle Band 21.43
20-Day Bollinger Upper Band 28.45
Beta -0.27
RSI 37.21
50-Day SMA 19.99
200-Day SMA 23.76

System

Modified 3/28/2024 5:32:08 PM EST